Business Model & Revenue
Cardiff Oncology is a clinical-stage biotechnology company with a single clinical asset, onvansertib, and essentially no revenue: $171K of quarterly royalty income against a $9.39M quarterly operating budget funded from a $33.8M treasury. The model is classic asset-centric biotech — concentrate capital in one differentiated molecule, de-risk it through randomized data and FDA designations, and monetize through a registrational partnership, licensing deal, or acquisition. The Q3 expense line shows discipline: operating expenses fell 22% year-over-year and net loss narrowed 21%, stretching the cash runway without slowing the clinical program.
The asset economics matter. Onvansertib is a highly specific, oral PLK1 inhibitor — a pill, not an infusion — being positioned as an add-on to existing first-line standard of care (FOLFIRI plus bevacizumab) in RAS-mutated metastatic colorectal cancer. Add-on positioning to established chemotherapy backbones is the lowest-friction commercial path in oncology: no displacement of a incumbent regimen required, with the value captured in the delta between 72.2% and 42.1% response rates. PLK1 inhibition's RAS-agnostic mechanism means the same molecule has earned Orphan Drug designations in chronic myelomonocytic leukemia (October 2026) and small cell lung cancer (November 2026) — free optionality on a platform the market is valuing near zero.
The binding constraint is funding scale. A registrational colorectal cancer trial costs far more than $33.8M, and management says so explicitly — additional financing is necessary. That means dilution, partnership, or both, and it is the single variable that determines whether Fast Track becomes value or vapor. With 31 employees and a Phase 2 asset carrying FDA designations, Cardiff is exactly the profile strategic acquirers screen for — recent orphan-oncology deals have consistently cleared Cardiff's current enterprise value. Notably, Fast Track itself improves the financing hand: rolling review eligibility, more frequent FDA meetings, and Priority Review and Accelerated Approval pathways materially raise the probability-weighted value of the asset to any partner running the deal math, which strengthens Cardiff's negotiating position precisely when it needs to transact.
Financial Highlights
Q3 2026 vs Q3 2025 (three months ended September 30, 2026)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Royalty Revenue | $171K | $120K | +43% |
| Operating Expenses | $9.39M | $12.02M | -22% |
| Net Loss | ($8.86M) | ($11.21M) | -21% |
CRDF-004 Randomized Phase 2 (first-line RAS-mutated mCRC; data as of September 28, 2026)
| Endpoint | 30 mg Onvansertib + FOLFIRI/bev | SoC (FOLFIRI/bev) |
|---|---|---|
| Confirmed ORR (ITT) | 72.2% | 42.1% |
| Median PFS | Not reached | ≈11 months (combined SoC arms) |
| Minimum treatment duration, 30 mg arm | 21+ months for all remaining patients | — |
| Patients on treatment at cutoff | 5 (onvansertib arms) | 6 + 1 SoC |
Trailing Twelve Months
| Metric | TTM |
|---|---|
| Revenue | $559K |
| Net Loss | ($37.68M) |
Balance Sheet Snapshot (September 30, 2026)
| Item | Amount |
|---|---|
| Cash & Short-Term Investments | $33.8M |
| Cash per Share | $0.43 |
| Shares Outstanding | 77.80M |
| Float | 75.38M |
| Short Interest | 12.26M shares (15.8% of shares; 28.8 days to cover) |
| Debt / Equity | 0.01 |
| Runway | Through Q3 2027 |
Guidance: None formal. Company states funding through Q3 2027 and that additional financing remains necessary for the planned registrational Phase 3 trial.
Cash consumption: The Q3 net loss of $8.86 million against $33.8 million of cash implies roughly twelve months of runway at the current loss rate before any proceeds from financing, consistent with the company's own Q3 2027 guidance. Quarterly operating expenses have been cut from $12.02 million to $9.39 million year-over-year, and the 22% reduction compounds with each quarter — but a registrational colorectal cancer trial's site activation, manufacturing, and statistical costs would swamp the current budget without new capital, which is why the funding event is the dominant near-term variable. Every quarter without an equity raise raises the odds that the raise comes as a partnership instead.
Competitive Landscape
Cardiff operates in RAS-mutated oncology — the most competitive target in cancer drug development — but from an orthogonal angle. The crowded money is in direct KRAS inhibitors (G12C and variant-specific); onvansertib instead inhibits PLK1, a downstream dependency that RAS-mutant tumors share regardless of variant. In first-line RAS-mutated mCRC specifically, there is no approved mutation-directed therapy, which is the unmet need Fast Track cites.
-
Amgen (AMGN): Lumakras (sotorasib), the KRAS G12C pioneer, approved in later-line KRAS G12C-mutated CRC in combination with panitumumab; confined to the G12C subset while onvansertib's claim covers all RAS mutations — the key differentiator in first-line.
-
Bristol-Myers Squibb (BMY): Owns adagrasib (via Mirati) with its own KRAS G12C colorectal program; same subset limitation, same validation of demand for RAS-directed therapy.
-
Revolution Medicines (RVMD): Developing pan-RAS(ON) inhibitors including multi-selective constructs; the most conceptually similar approach to RAS-agnostic coverage, but direct inhibitors rather than a chemo add-on, and earlier in colorectal cancer.
-
Eli Lilly (LLY): KRAS G12C inhibitor in development with large-scale oncology commercialization muscle; validates how quickly the RAS landscape can crowd once data mature.
-
Standard of care (generic FOLFIRI + bevacizumab biosimilars): The true incumbent; onvansertib's 30-point ORR improvement is measured against exactly this backbone, meaning adoption requires no regimen displacement — only an add-on decision.
Moats:
- Randomized, controlled Phase 2 data — a 30-point confirmed ORR delta versus contemporaneous control, not a single-arm readout
- FDA Fast Track plus two Orphan Drug designations (CMML, SCLC) on one molecule
- RAS-agnostic oral mechanism spanning all RAS variants rather than G12C subsets
- Durable exposure data — 21-plus months on treatment for all remaining 30 mg patients, a treatment-duration record any diligence team can verify
Catalysts
-
Registrational Phase 3 planning and financing — next 6-12 months: End-of-Phase 2 interactions, trial design disclosure, and crucially the funding structure (partnership, licensing, or equity) that management says is necessary
-
Maturing CRDF-004 survival data: Median PFS not reached in the 30 mg arm; each additional event-free month for patients already 21-plus months on treatment extends the documented tail, and the final PFS disclosure is the single hardest datapoint for the bear case to survive
-
Fast Track execution benefits: Rolling review eligibility and more frequent FDA interactions compress the registrational timeline if Phase 3 proceeds
-
CMML and SCLC expansion: Fresh Orphan Drug designations (October and November 2026) in indications with smaller trial requirements — a second shot on goal that could advance with modest capital
-
Short-covering mechanics: 15.8% of shares short with 28.8 days to cover and a float of 75.4M shares; Phase 3 financing clarity could force an unwind
Key Risks
- Financing and dilution — $33.8M cash funds only through Q3 2027 and management explicitly states additional financing is necessary for the planned Phase 3; shares outstanding already rose 11.4% in one quarter
- Small randomized trial — the ORR delta comes from a Phase 2 in which 5 onvansertib-arm patients remained on treatment at the September 28, 2026 cutoff; the pivotal population must reproduce it
- Immature survival data — median PFS is not reached in the 30 mg arm; final progression-free and overall survival readouts could compress the ≈11-month control delta
- Competitive encroachment — Amgen and Bristol-Myers Squibb KRAS G12C combinations and Revolution Medicines' pan-RAS pipeline are advancing in RAS-mutated disease and could crowd first-line combinations
- Violent micro-cap dynamics — 28.8 days-to-cover short interest, a stock down 67.6% over 52 weeks, and a 19.8% pre-market swing range; position sizing must assume 30%+ drawdowns
Our Thesis
First-line RAS-mutated metastatic colorectal cancer is a population with no therapy approved specifically for its defining mutation — an unmet need the FDA has now formally acknowledged twice in one month (Orphan Drug designations for CMML in October and small cell lung cancer in November, Fast Track today). Onvansertib's differentiator is mechanism: a highly specific oral PLK1 inhibitor that exploits a vulnerability common to all RAS-mutant tumors rather than chasing individual KRAS variants like G12C drugs. The randomized CRDF-004 data are unusually clean for a Phase 2 — a 30-point confirmed ORR improvement over the standard-of-care arm (72.2% versus 42.1%), median PFS not reached in the 30 mg arm against ≈11 months combined for control, and durable exposure with all remaining 30 mg patients treated 21-plus months.
The valuation disconnect: a ≈$62 million market cap with $33.8 million of cash leaves ≈$28 million of enterprise value for an asset with Fast Track, two Orphan Drug designations, randomized Phase 2 data, and a registrational trial planned. Our $1.30 target implies ≈$101 million market cap and ≈$67 million enterprise value — ≈2.4x current EV, still a discount to typical mid-stage oncology acquisition benchmarks. Cash of $0.43 per share covers 54% of the current price and runway through Q3 2027. Speculative Buy: Phase 3 financing requires dilution (shares already up 11.4% quarter-over-quarter), five onvansertib-arm patients were still on treatment at the September 28 cutoff, and 15.8% short interest with 28.8 days to cover guarantees violent two-way moves.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.